Natural killer cells could form the next generation of cancer immunotherapies, but in order to fulfill this promise, they’ll need to overcome some of the challenges of the first generation of cell ...

Ginkgo Bioworks’ swift moving business development team is slowing down long enough to load up some new chimeric antigen receptor (CAR) assets from Modulus Therapeutics. The deal will see Ginkgo pick ...

Modulus Alternatives, an alternative asset manager, today announced the Final Close of India Credit Opportunities Fund II (ICOF II) with commitments exceeding INR 700 crore. The Fund continues to ...

Joy in factory building and automation games is a spectrum. For the most engineering-brained, the efficiency of a perfectly balanced input-output system is king. For artists it's ...